Skip to content
The Science

The enteric-brain axis, engineered.

NooGut is a delivery-layer company. Our thesis is not about a molecule — it is about a route. By bypassing the gastric barrier and addressing the high-density neural substrate of the lower enteric nervous system, we eliminate the latency and attenuation that throttle every conventional delivery pathway.

500M+
Enteric neurons
Addressable substrate
94%
Modeled bioavailability
Enteric route
<15 min
Time to peak plasma
vs 2–6 hr oral
0
Hepatic first-pass steps
Route bypasses liver
Mechanism of Action

Two routes. One is throttled by design.

The conventional oral route forces every payload through an acidic holding queue and an opinionated hepatic processing stage before a fraction reaches circulation. The NooGut route addresses the enteric substrate directly.

Legacy Oral Route Bypassed
Oral intake
Gastric queue
Hepatic first-pass
Attenuated output
NooGut Enteric Route Active
The Disruptor™
Enteric substrate
Systemic circulation
Cranial uptake

No gastric queue. No hepatic first-pass. Payload reaches the systemic layer at line rate.

Bioavailability

Modeled uptake by delivery route.

Relative fraction of an administered payload estimated to reach systemic circulation, by route. The enteric route's advantage comes almost entirely from avoiding hepatic first-pass metabolism.

Source: internal computational modeling, NooGut Research Collective (2026).

Oral capsule 41%
Sublingual 62%
Transdermal patch 73%
NooGut Enteric™ 94%
Pharmacokinetics

Plasma concentration over time.

Modeled plasma concentration following a single protocol. The enteric route reaches a higher peak concentration (Cmax) far sooner (Tmax), with no first-pass attenuation.

TIME AFTER DEPLOYMENT (HOURS) → PLASMA CONC. →
NooGut Enteric™ · high Cmax, early Tmax Oral capsule · attenuated, delayed
Clinical Program

The NOOGUT-1 investigation.

Our flagship study is ongoing. We believe in shipping the thesis and hardening the evidence in parallel — the same discipline we apply to everything. We report our cohort honestly.

Primary endpoint
Δ subjective throughput (self-reported)
Secondary endpoint
Time-to-standup readiness
Cohort
n = 1 (the founder)
Design
Open-label, unblinded, unregistered
Status
Ongoing · peer review pending Series B
Safety & Tolerability

Well tolerated by the cohort.

Reported effects reflect the experience of our current cohort and should not be generalized to any population, because they mathematically cannot be.

Tolerability
Well tolerated by the cohort
Common effects
Elevated conviction, reduced patience for standups
Contraindications
Board meetings while on The Hard Fork™
Dependency profile
Behavioral; structurally internalized
References
  1. [1] Sölen, A., Ventureborne, C. (2026). Idle capacity in the lower enteric substrate: a computational reframing. The Enteric Journal of Applied Optimization, 4(2), 11–29. doi:10.9999/tejao.2026.0042
  2. [2] Rell, M., Anand, D. (2026). Closed-loop titration against recovery telemetry: preliminary field observations. Proceedings of Protocol Weekly, 12, 3–17. doi:10.9999/pw.2026.0117
  3. [3] Sölen, A. (2025). Proximity blindness and the century-long under-development of the second brain. Journal of Posterior Bioavailability, 1(1), 1–4. doi:10.9999/jpb.2025.0001
  4. [4] NooGut Research Collective. (2026). NOOGUT-1: an open-label investigation of enteric-route cognitive infrastructure (interim). Internal White Paper, unindexed. doi:pending

All figures reflect internal modeling. Citations are illustrative of our research direction. These statements have not been evaluated by any regulatory body with jurisdiction over your enteric-brain axis. Not intended to diagnose, treat, cure, or prevent underperformance.

The thesis is settled. The substrate is waiting.